• ESAB is trading 4.1% up at $86.38, also supported by Oppenheimer adjusting its price target to $135 from $140, maintaining an Outperform rating.
  • The stock is rebounding after a sharp drop linked to concerns over its debt-funded Eddyfi acquisition and potential 2026 earnings dilution.
  • The upward move aligns with a broader market recovery, as major U.S. indices gained between 0.8% and 1.3% following Monday's weakness.